PGEN Stock Analysis: Precigen | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.392m USD | 12M Return: 91.1% | US74017N1054 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 25.4M
Qual. Beats: 0
Rev. Trend: 64.5%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Precigen (NASDAQ: PGEN) is a U.S.-based, clinical-stage biopharmaceutical company that develops gene and cell therapies targeting immuno-oncology, autoimmune disorders, and infectious diseases. The company operates two core therapeutic platforms: AdenoVerse, which uses proprietary adenoviral vectors for gene delivery of therapeutic effectors and vaccine antigens, and UltraCAR-T, which enables the manufacturing of chimeric antigen receptor T-cell therapies for cancer patients.
Precigens pipeline includes several clinical-stage candidates built on these platforms, including UltraCAR-T programs PRGN-3005 (ovarian and related cancers), PRGN-3006 (acute myeloid leukemia and high-risk myelodysplastic syndromes), and PRGN-3007 (ROR1-positive tumors), as well as AdenoVerse programs PRGN-2009 (HPV-positive solid tumors) and PRGN-2012 (recurrent respiratory papillomatosis). The company also markets UltraPorator, a proprietary electroporation device used in cell therapy manufacturing. Precigen was founded in 1998 as Intrexon Corporation, adopted its current name in February 2020, and is headquartered in Germantown, Maryland.
As a clinical-stage biotechnology company with no currently commercialized products, Precigens business model centers on advancing early- and mid-stage drug candidates through clinical trials, with funding typically derived from equity financings, partnerships, and non-dilutive sources rather than product revenue. The broader gene and cell therapy sector remains capital-intensive and heavily dependent on clinical trial outcomes and regulatory milestones to drive valuation.
- PRGN-2012 Phase 2 data in HPV-related papillomatosis expected this quarter
- Rising R&D cash burn threatens runway amid clinical-stage operations
- UltraCAR-T pipeline faces competition from approved Gilead and Bristol CAR-T therapies
| Net Income: -157.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.68 > 0.02 and ΔFCF/TA 0.46 > 1.0 |
| NWC/Revenue: 122.5% < 20% (prev 911.6%; Δ -789.0% < -1%) |
| CFO/TA -0.67 > 3% & CFO -114.2m > Net Income -157.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.58 > 1.5 & < 3 |
| Outstanding Shares: last quarter (413.7m) vs 12m ago 39.55% < -2% |
| Gross Margin: 89.56% > 18% (prev -18.71%; Δ 108.3% > 0.5%) |
| Asset Turnover: 62.98% > 50% (prev 4.26%; Δ 58.72% > 0%) |
| Interest Coverage Ratio: -4.06 > 6 (EBIT TTM -39.5m / Interest Expense TTM 9.73m) |
| A: 0.62 (Total Current Assets 134.4m - Total Current Liabilities 29.4m) / Total Assets 170.3m |
| B: -13.68 (Retained Earnings -2.33b / Total Assets 170.3m) |
| C: -0.29 (EBIT TTM -39.5m / Avg Total Assets 136.1m) |
| D: 0.34 (Book Value of Equity 43.6m / Total Liabilities 126.7m) |
| Altman-Z'' = -42.13 = D |
| DSRI: 3.0 (Receivables 72.0m/571k, Revenue 85.7m/4.34m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.58 (AQ_t 0.11 / AQ_t-1 0.19) |
| SGI: 19.75 (Revenue 85.7m / 4.34m) |
| TATA: -0.26 (NI -157.7m - CFO -114.2m) / TA 170.3m) |
| Beneish M = 11.79 (Cap -4..+1) = D |
As of September 18, 2026, the stock is trading at USD 7.44 with a total of 8,221,900 shares traded. Over the past week, the price has changed by +9.34%, over one month by +13.51%, over three months by +56.53% and over the past year by +91.13%.
Current recommended Stop Loss: 7.00 (which is 5.9% or 1.4 ATR below the current price).
Precigen has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold PGEN.
- StrongBuy: 1
- Buy: 2
- Hold: 0
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 14.5 | 94.9% |
P/E Forward = 15.4321
P/S = 27.7832
P/B = 55.83
Revenue TTM = 85.7m USD
EBIT TTM = -39.5m USD
EBITDA TTM = -35.4m USD
Long Term Debt = 93.9m USD (from longTermDebt, last quarter)
Short Term Debt = 1.05m USD (from shortTermDebt, last quarter)
Debt = 102.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 4.46m
Net Debt = 64.6m USD (calculated: Debt 102.8m - CCE 38.2m)
Enterprise Value = 2.46b USD (2.39b + Debt 102.8m - CCE 38.2m)
Interest Coverage Ratio = -4.06 (Ebit TTM -39.5m / Interest Expense TTM 9.73m)
EV/FCF = -21.21x (Enterprise Value 2.46b / FCF TTM -115.8m)
FCF Yield = -4.72% (FCF TTM -115.8m / Enterprise Value 2.46b)
FCF Margin = -135.1% (FCF TTM -115.8m / Revenue TTM 85.7m)
Net Margin = -184.0% (Net Income TTM -157.7m / Revenue TTM 85.7m)
Gross Margin = 89.56% ((Revenue TTM 85.7m - Cost of Revenue TTM 8.95m) / Revenue TTM)
Gross Margin QoQ = 94.90% (prev 87.63%)
Tobins Q-Ratio = 14.42 (Enterprise Value 2.46b / Total Assets 170.3m)
Interest Expense / Debt = 9.46% (Interest Expense 9.73m / Debt 102.8m)
Taxrate = 0.0% (0.0 / 20.1m)
NOPAT = -39.5m (EBIT -39.5m * (1 - 0.00%)) [loss with tax shield]
Current Ratio = 4.58 (Total Current Assets 134.4m / Total Current Liabilities 29.4m)
Debt / Equity = 2.36 (Debt 102.8m / totalStockholderEquity, last quarter 43.6m)
Debt / EBITDA = -1.83 (negative EBITDA) (Net Debt 64.6m / EBITDA -35.4m)
Debt / FCF = -0.56 (negative FCF - burning cash) (Net Debt 64.6m / FCF TTM -115.8m)
Total Stockholder Equity = 31.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -115.9% (out of range, set to none)
RoE = -498.3% (Net Income TTM -157.7m / Total Stockholder Equity 31.6m)
RoCE = -31.47% (EBIT -39.5m / Capital Employed (Equity 31.6m + L.T.Debt 93.9m))
RoIC = -28.68% (negative operating profit) (NOPAT -39.5m / Invested Capital 137.7m)
WACC = 5.87% (E(2.39b)/V(2.49b) * Re(5.72%) + D(102.8m)/V(2.49b) * Rd(9.46%) * (1-Tc(0.0)))
Discount Rate = 5.72% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 84.43 | Cagr: 25.26%
[DCF] Fair Price = unknown (Cash Flow -115.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.20 | # QB: 0
Revenue Correlation: 64.52 | Revenue CAGR: 97.76% | SUE: 4.0 | # QB: 2
EPS current Quarter (2026-09-30): EPS=0.08 | Chg30d=N/A | Revisions=+0% | Analysts=3
EPS current Year (2026-12-31): EPS=0.22 | Chg30d=N/A | Revisions=+0% | GrowthEPS=+116.1% | GrowthRev=+2305.7%
EPS next Year (2027-12-31): EPS=0.68 | Chg30d=+241.20% | Revisions=+40% | GrowthEPS=+209.8% | GrowthRev=+95.0%
[Analyst] Revisions Ratio: +40% (up=2, down=0)